About BioPact

Biopact is a Molecular Rebar Design Company focusing on nanoscale biomaterials company developing the MGMR intracellular delivery vehicle. MGMR is a cellular-engineering tool for biomanufacturing and agricultural processes which value efficient delivery of RNAs, peptides, and genetic materials.

MGMR is a highly-efficient intracellular delivery vehicle, consisting of a stabile dispersion of hollow, nanoscale tubules approximately 1/10,000th the width of a human hair. The high aspect-ratio, nanoscale profile of MGMR allows it to readily penetrate cells without compromising membrane integrity or inducing cytotoxicity. Its high surface-to-volume ratio and tunable surface chemistry allow it to readily transport both small and large-molecular payloads into the cytoplasm, including growth factors, oligonucleotides, proteins and gene-editing complexes.

Biopact has evaluated the cytotoxicity profile of MGMR across multiple cell-lines and investigated safety and efficacy in murine biodistribution and clearance models. Our in vivo studies demonstrate that MGMR is biologically-inert, well-tolerated and rapidly cleared from non-targeted tissues. In a murine therapeutic model, MGMR loaded with doxorubicin (Dox) demonstrated a remarkable capability to rapidly concentrate drug in targeted tissues and extend half-life of its molecular cargo.

Promising assessments of intracellular delivery performance in different eukaryotic cell-types suggest the potential for developing MGMR as a biomolecular delivery vehicle for various expression platforms and cell-factories of interest to agricultural and industrial applications, including mammalian cell-lines, yeasts, bacteria and plants. Robust cellular uptake observed with MGMR offers the potential to deliver molecular payloads to difficult-to-penetrate cell-types or those acutely sensitive to detergents and other conventional methods for transmembrane delivery.

website icon
Website
employees icon
Employees
industry icon
Industry
Biotechnology Research
location icon
Headquarter
12310 Trail Driver Street, Austin, Texas 78737, US
description icon
Founded
2014
description icon
Keywords
Drug Delivery, Nanotechnology, Rnai, Genetic Engineering, Gene Delivery, Protein Delivery, Agricultural Bioengineering, Antibody Delivery, Cellular Delivery, Genetically Modified Organisms, Intracellular Delivery, Strain Development, Trans-Membrane Delivery

Frequently Asked Questions about BioPact

Who is the CEO of BioPact?

Kent Phelps is the CEO of BioPact. To contact Kent Phelps email at [email protected] or [email protected]. Or you may call +18005617087, +14804679000 or 800-674-3582

Supercharge your
Prospecting &
Outreach with
ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.

Discover the source of our data

Learn more